Advisory Research’s Ultragenyx Pharmaceutical RARE Stock Holding History

Advisory Research’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,403	Closed	-$610K	–	382
2020 Q4	$610K	Sell	4,403 -8,244	-65%	-$978K	0.04%	243
2020 Q3	$1.04M	Buy	12,647 +3,868	+44%	+$321K	0.1%	173
2020 Q2	$687K	Buy	+8,779	New	+$581K	0.06%	211
2018 Q4	–	Sell	-22,469	Closed	-$1.72M	–	388
2018 Q3	$1.72M	Buy	+22,469	New	+$1.83M	0.03%	212
2017 Q2	–	Sell	-22,204	Closed	-$1.5M	–	447
2017 Q1	$1.5M	Buy	+22,204	New	+$1.69M	0.02%	284

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Advisory Research's RARE Position: Q1 2021 in Review

Advisory Research sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2021, closing a stake of 4,403 shares — an estimated $610K sold.

Advisory Research first reported a position in RARE in Q1 2017 and held it in 5 quarters. The position peaked at $1.72M in Q3 2018. 254 funds tracked by Wall St. Rank hold RARE as of Q1 2021.

Advisory Research reported no remaining Ultragenyx Pharmaceutical position as of Q1 2021 after selling out during the quarter.
Advisory Research sold 4,403 Ultragenyx Pharmaceutical shares in Q1 2021, an estimated $610K.
Advisory Research first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and held it in 5 quarters.
Advisory Research's Ultragenyx Pharmaceutical position peaked at $1.72M in Q3 2018.
254 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2021.

Based on Advisory Research's 13F filing for Q1 2021, filed 12 May 2021.